Ipsen – Half year statement – 2022 12 31
- 06 January 2023 - 1 mins read
This article or press release has no online content. Please download the associated documents for more information.
Attachment
19 September 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 37 – 2023
12 September 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2023
08 September 2023
1 mins read
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
05 September 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 35 – 2023
04 September 2023
5 mins read
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
01 September 2023
6 mins read
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
29 August 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 34 – 2023
22 August 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 33 – 2023
16 August 2023
12 mins read
US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
08 August 2023
1 mins read